Group 1 - The core point of the news is that Yuan Dong Bio experienced a 5.02% drop in stock price, currently trading at 53.30 CNY per share, with a total market capitalization of 9.409 billion CNY [1] - The company, Chengdu Yuan Dong Bio-Pharmaceutical Co., Ltd., was established on June 1, 2009, and listed on September 2, 2020. Its main business involves the research, production, and sales of chemical raw materials and chemical drug formulations [1] - The revenue composition of the company includes 78.75% from formulation sales, 9.22% from raw material sales, 6.79% from technical services and transfers, 4.01% from CMO/CDMO, and 1.22% from other sources [1] Group 2 - From the perspective of fund holdings, one fund under Southern Fund has Yuan Dong Bio as a top ten holding. The Southern SSE STAR Market Comprehensive ETF Linked A (023731) held 43 shares in the third quarter, ranking as the tenth largest holding [2] - The estimated floating loss for the fund today is approximately 121.26 CNY [2] - The Southern SSE STAR Market Comprehensive ETF Linked A (023731) was established on April 8, 2025, with a latest scale of 97.6034 million CNY and a cumulative return of 34.95% since inception [2]

中银证券健康产业混合（002938）基金经理为李明蔚。 截至发稿，李明蔚累计任职时间2年272天，现任基金资产总规模1.59亿元，任职期间最佳基金回 报-5.77%， 任职期间最差基金回报-5.77%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 11月19日，苑东生物跌5.02%，截至发稿，报53.30元/股，成交6216.42万元，换手率0.65%，总市值 94.09亿元。 资料显示，成都苑东生物制药股份有限公司位于四川省成都市双流区安康路8号，成立日期2009年6月1 日，上市日期2020年9月2日，公司主营业务涉及化学原料药和化学药制剂的研发、生产与销售。主营业 务收入构成为：制剂销售78.75%，原料药销售9.22%，技术服务及转让6.79%，CMO/CDMO4.01%，其 他1.22%。 从基金十大重仓股角度 数据显示，中银证券旗下1只基金重仓苑东生物。中银证券健康产业混合（002938）三季度持有股数 14.6万股，占基金净值比例为5.07%，位居第九大 ...

Group 1: Regulatory Developments - The National Healthcare Security Administration (NHSA) held a public seminar on the adjustment of the Disease-Based Payment Grouping Scheme 3.0, engaging with representatives from 22 hospitals [1] - The National Medical Products Administration (NMPA) issued technical guidelines for the pharmaceutical research and evaluation of recombinant glycoprotein hormone products [2] Group 2: Clinical Trials and Approvals - Maiwei Biotech announced that its 9MW3811 injection for pathological scars has received approval for a Phase II clinical trial, with plans to start by the end of 2025 [3] - Yuandong Biotech reported that its YLSH003 injection for advanced solid tumors has initiated Phase I/II clinical trials, with the first subject successfully enrolled [4] - Novartis received FDA approval for Remibrutinib tablets for treating chronic spontaneous urticaria (CSU) in adults who remain symptomatic after H1 antihistamine treatment [5] Group 3: Market Activities - Real Bio Technology has submitted a listing application to the Hong Kong Stock Exchange, marking its third attempt to go public [6] - Kangfang Biotech announced the completion of the first patient dosing in a Phase I trial for its personalized mRNA vaccine AK154, used in combination with other therapies for postoperative pancreatic cancer treatment [6] Group 4: Research Breakthroughs - Researchers from Monash University and the University of Warwick discovered a promising antibiotic during the production process of a common drug, effective against "superbugs" like methicillin-resistant Staphylococcus aureus [7]

Core Viewpoint - Chengdu Yuandong Biopharmaceutical Co., Ltd. has announced the initiation of I/II phase clinical trials for its novel antibody-drug conjugate YLSH003, aimed at treating advanced solid tumors, with the first subject successfully enrolled [1][3]. Group 1: Drug Overview - YLSH003 is a new type of antibody-drug conjugate targeting Tissue Factor (TF), which is implicated in the recurrence and metastasis of many solid tumors [1][2]. - The drug is developed using a high-affinity humanized IgG1 antibody and a small molecule topoisomerase I inhibitor, utilizing the Uni-linker ADC technology platform [2]. - Preclinical studies indicate that YLSH003 has high anti-tumor activity and potential superior safety, offering better treatment options for patients with advanced solid tumors [2]. Group 2: Clinical Trial Details - YLSH003 received acceptance from the National Medical Products Administration (NMPA) in July 2025 and was granted a clinical trial approval notice in September 2025 [3]. - The I/II phase clinical study aims to evaluate the safety, tolerability, pharmacokinetics, and efficacy of YLSH003 in patients with advanced solid tumors, with the I phase focusing on dose escalation and the II phase on efficacy at the recommended dose [3]. - The first subject in the I phase has been successfully enrolled, and recruitment for additional subjects is progressing rapidly [3].

Group 1 - Digital Zhengtong's subsidiary Baoding Jindi won a bid for a smart water project in Jinan, with a total contract value of 109 million yuan, of which Baoding Jindi's share is approximately 77 million yuan [1] - Lingzhi Software plans to acquire 100% equity of Kaimiride through a combination of cash and stock issuance, with the final transaction price yet to be determined [1] - Tianjin Port's subsidiary plans to transfer 60% equity of China Railway Storage and Transportation, with an estimated value of 37.54 million yuan for the entire equity [2] Group 2 - New Wufeng reported a 56.97% year-on-year increase in pig sales in October, selling 610,000 pigs [3] - New Peng Co. announced a joint investment of approximately 15 million USD with Jabil to build a battery storage box project in Thailand [4] - Maiwei Bio received approval for a clinical trial of its 9MW3811 injection for pathological scars [6] Group 3 - Jiangsu Sopo completed maintenance and resumed production of its methanol and acetic acid facilities [8] - Luoniushan reported a 24.65% year-on-year increase in pig sales revenue in October, totaling 116 million yuan [9][10] - Zhongbei Communication signed a 1 billion yuan comprehensive computing service framework agreement with Xiamen Hongxin Electronics [11] Group 4 - Huayang New Materials announced the resignation of its general manager, Wu Yuehua [12] - Zhongxin Co. used 50 million yuan of idle funds to purchase structured deposits with expected annual returns between 0.55% and 2.05% [14] - Huajian Group's subsidiary signed a construction engineering design contract worth 96.54 million yuan [16] Group 5 - Jianyou Co. received FDA approval for a new production site for its injectable drug [17] - Beilu Pharmaceutical obtained a drug registration certificate for its iodine mepivacaine injection, which is included in the national medical insurance catalog [19] - *ST Yuancheng's stock will be suspended due to falling below the market cap threshold for delisting [20] Group 6 - Xiantan Co. reported a 9.3% year-on-year increase in chicken product sales revenue in October, totaling 503 million yuan [21] - Huanxu Electronics reported an 8.93% year-on-year decrease in consolidated revenue for October, amounting to 5.598 billion yuan [23] - Yisheng Co. reported a 22.97% year-on-year decrease in white feather chicken seed sales revenue in October [25] Group 7 - Yuandong Bio initiated a Phase I/II clinical trial for its ADC drug YLSH003 targeting advanced solid tumors [25] - Xiaoming Co. reported a 34.89% year-on-year decrease in chicken product sales revenue in October [26] - Nanjiao Food reported a 5.27% year-on-year decrease in consolidated revenue for October, totaling 235 million yuan [28] Group 8 - Chuangye Huikang announced a potential change in control, leading to a temporary stock suspension [30] - Tangrenshen reported a 17.91% year-on-year decrease in pig sales revenue in October, totaling 828 million yuan [32][33] - Wancheng Group plans to distribute a cash dividend of 1.5 yuan per 10 shares to shareholders [34] Group 9 - Kangguan Technology plans to distribute a cash dividend of 3.6 yuan per 10 shares to shareholders [36] - Shoudu Online's executive plans to reduce holdings of up to 19,400 shares [38] - Maolai Optical received approval for the issuance of convertible bonds [40] Group 10 - Jinkai New Energy plans to distribute a cash dividend of 0.1 yuan per share to shareholders [41] - Tianchen Medical raised the upper limit for share repurchase to 70 yuan per share [42] - Tianmu Lake used 38 million yuan of idle funds to purchase structured deposits [43]

Core Viewpoint - Yuan Dong Biotech (688513) announced that its wholly-owned subsidiary, Shanghai Youluo, has initiated Phase I/II clinical trials for its self-developed Class I biological drug, YLSH003, targeting advanced solid tumors, with the first subject successfully enrolled for treatment recently [1] Group 1 - The company is advancing its clinical research with YLSH003, which is a significant step in its drug development pipeline [1] - The initiation of clinical trials indicates the company's commitment to addressing unmet medical needs in oncology [1] - The successful enrollment of the first subject marks a critical milestone in the development process of YLSH003 [1]

证券代码：688513 证券简称：苑东生物 公告编号：2025-079 目前，上海优洛已就该药品的相关技术提交了 1 项国际专利申请。针对 TF 靶点开发的 ADC 药物，国外已有 Tivdak®上市，用于治疗宫颈癌；国内则有乐 普生物、信诺维等公司正在开展不同阶段的临床研究，适应症主要集中于宫颈癌、 卵巢癌及胰腺癌。 1 成都苑东生物制药股份有限公司 关于自愿披露注射用 YLSH003 启动 I/II 期临床试验 并完成首例受试者入组的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都苑东生物制药股份有限公司（以下简称"公司"）全资子公司优洛生物（上 海）有限公司（以下简称"上海优洛"）自主研发的 1 类生物药注射用 YLSH003 正在开展用于晚期实体瘤的 I/II 期临床试验，首例受试者已于近日成功入组给药。 现将相关情况公告如下： 一、注射用 YLSH003 的基本情况 注射用 YLSH003 是一种靶向组织因子（Tissue Factor，TF）的新型抗体偶 联药物（antibody-drug conju ...

Core Viewpoint - Yuan Dong Biotech (688513.SH) announced that its wholly-owned subsidiary, Shanghai Youluo, has initiated Phase I/II clinical trials for its self-developed antibody-drug conjugate, YLSH003, targeting advanced solid tumors, with the first patient successfully enrolled for treatment [1] Group 1: Product Development - YLSH003 is a novel antibody-drug conjugate designed to target Tissue Factor (TF), which plays a crucial role in the coagulation process and is highly expressed in advanced solid tumors [1] - The development of YLSH003 aims to address the recurrence and metastasis issues associated with high TF expression in late-stage solid tumors [1]

Core Viewpoint - Yuan Dong Biotech (688513.SH) announced that its wholly-owned subsidiary, You Luo Biotech (Shanghai) Co., Ltd., has initiated I/II clinical trials for its self-developed antibody-drug conjugate, YLSH003, targeting advanced solid tumors, with the first patient successfully enrolled for treatment [1] Group 1: Product Development - YLSH003 is a novel antibody-drug conjugate designed to target Tissue Factor (TF), which plays a crucial role in the coagulation process and is highly expressed in advanced solid tumors [1] - The development of YLSH003 aims to address the recurrence and metastasis issues associated with high TF expression in late-stage solid tumors [1] Group 2: Clinical Trials - The I/II phase clinical trials for YLSH003 are currently underway, marking a significant step in the company's research and development efforts in oncology [1] - The successful enrollment of the first patient indicates progress in the clinical trial process and potential future advancements in treatment options for patients with advanced solid tumors [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Shanghai Youlu, has initiated clinical trials for a new biopharmaceutical, YLSH003, targeting advanced solid tumors, with the first patient successfully enrolled for treatment [1] Group 1: Product Development - YLSH003 is a novel antibody-drug conjugate targeting tissue factor, and the company has submitted an international patent application for the related technology [1] - The clinical trials consist of Phase I and Phase II studies, with Phase I focusing on safety and tolerability, while Phase II will assess efficacy [1] - The drug is expected to be accepted and approved by 2025, with the first patient already enrolled in Phase I and recruitment for additional subjects ongoing [1] Group 2: Market Context - The pharmaceutical development process is characterized by high risks, and the timeline for project approval and outcomes remains uncertain [1]